Introduction
Kidney fibrosis is characterized by over-production and deposition of extracellular matrix and is considered to be a crucial factor in driving chronic kidney disease (CKD) towards kidney failure [1, 2] . There is currently no effective treatment targeting kidney fibrosis. Transforming growth factor β (TGF-β) plays an important role in the development of tissue fibrosis [3] . However, the inhibition of TGF-β to prevent fibrosis would also abrogate its anti-inflammatory and wound-healing effects [4, 5] . The contrasting effects of TGF-β (profibrotic versus anti-inflammatory) have posed a considerable challenge in the treatment of fibrotic diseases affecting the kidneys and other organs. However, we have recently described the role of β-catenin/Foxo in the redirection of TGF-β signaling from an undesirable profibrotic to a beneficial anti-inflammatory function [6] .
β-catenin binds to members of the T-cell factor (TCF)/ lymphoid enhancer binding factor in the Wnt signaling pathway. β-catenin/TCF is central to all the profibrotic pathways, including TGF-β/Smad, integrin/ILK, and Wnt/βcatenin pathways [7] [8] [9] . In addition, β-catenin also binds to Forkhead box O (Foxo) proteins that belong to the Forkhead family of transcription factors, which play important roles in the control of cell differentiation, proliferation, and survival [10] . The role of Foxo proteins in the regulation of cell survival has been described by Greer and Brunet [11] .
Both TCF and Foxo bind to the armadillo repeats 1-7 on β-catenin [12] . β-catenin, in turn, may play a dual role, depending on its binding to either TCF or Foxo. β-catenin promotes fibrosis through its interactions with TCF, while its interactions with Foxo transcription factors may inhibit the β-catenin/TCF functions [13, 14] . In a previous study, we found that ICG-001, a small molecule inhibitor, prevented β-catenin/TCF interaction, shifting β-catenin towards Foxo binding, thereby reducing the β-catenin/ TCF-mediated profibrotic effects of TGF-β while enhancing the β-catenin/Foxo-mediated anti-inflammatory effects [6] . However, whether β-catenin/Foxo protects against the profibrotic effects of TGF-β remains unknown.
In the current study, we examined β-catenin/Foxo and β-catenin/TCF interactions using human kidney biopsies from patients with CKD due to diabetic nephropathy, hypertensive nephropathy, IgA nephropathy, focal segmental glomerulosclerosis (FSGS), mesangiocapillary glomerulonephritis (MCGN), medullary cystic diseases, as well as from patients following a kidney transplant. The effect of β-catenin/Foxo interaction versus β-catenin/TCF on TGF-β-induced profibrotic changes was examined in tubular epithelial cells in vitro by CRISPR/cas9-mediated knockout of Foxo1 or TCF1 and in a kidney fibrosis model, unilateral ureteric obstruction (UUO). We showed that the binding of β-catenin to Foxo protected against TGF-β-induced profibrotic effects and ameliorated kidney fibrosis.
Materials and methods

Human kidney biopsies
Paraffin-embedded human kidney biopsies from patients with thin basement membrane nephropathy (0-5% fibrosis score, considered as "kidney biopsies with little fibrosis"), diabetic nephropathy, kidney transplant, hypertensive nephropathy, IgA nephropathy, and other kidney diseases were obtained from the Department of Anatomical Pathology, Westmead Hospital. The study of human kidney tissue was approved by the Human Research Ethics Committee of Western Sydney Local Health District (WSLHD).
Cell cultures
Mouse tubular epithelial C1.1 cells [15] (a kind gift from the laboratory of Dr Rudolf Wuthrich, Switzerland) were cultured in DMEM:HAM's F12 (1:1 v/v) medium (Invitrogen) containing 1 M HEPES (Invitrogen), MEM NEAA (Invitrogen), 5 mg/ml insulin (Sigma), 1.25 ng/ml prostaglandin E1 (Cayman Chemicals, Ann Arbor, MI), 0.0338 ng/ml 3,3,5-triiodothyronine (Sigma), 5 mg/ml hydrocortisone (Sigma), 1.73 ng/ml transferrin (Sigma), 18 ng/ml sodium selenite (Sigma), and 5% fetal bovine serum (FBS) (Sigma-Aldrich) at 37°C, in 5% CO 2 . For treatment of cells, serum-supplemented media were replaced with serum-free media.
Generation of Foxo1 KO cell line and TCF1 KO cell line by CRISPR/cas9
To generate Foxo1 KO C1.1 cell lines, we co-transfected Foxo1 CRISPR/cas9 KO plasmid with a Foxo1 HDR plasmid (Santa Cruz Biotechnology, Inc), following the manufacturer's instructions. In brief, C1.1 cells were transfected and incubated for 24 h under conditions normally used to culture the cells. Media were replaced 24 h post-transfection. Puromycin antibiotic (2 μg/ml) was added after two passages of the cells to allow for positive selection of transfected cells. Similarly, TCF1 gene was knocked out using TCF1 double nickase plasmid (Santa Cruz Biotechnology, Inc).
KO was verified by Western blot of Foxo1 and TCF1 expression and fluorescence microscopy for the RFP/GFP signal.
Cell treatments
Subconfluent cultures of control C1.1, Foxo1 KO C1.1, and TCF1 KO C1.1 cells were rinsed with PBS (Invitrogen) and then treated with rhTGF-β1 (3 ng/ml, Biosource) with or without ICG-001 (5 µM, Sigma). After 48 h of treatment, cells were washed twice with DPBS (Gibco) and either processed for immunofluorescence microscopy or lysed with cold RIPA buffer (Sigma Aldrich), PMSF (1 mM, Sigma) and protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). Cell lysates were collected and sonicated for 5 min thrice, centrifuged at 10,000 rpm for 12 min at 4°C, and stored at −20°C until protein analysis was performed. For transfection experiments, C1.1 or TCF KO cells were transiently transfected with F-TrCP-Ecad plasmid by Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. F-TrCP-Ecad plasmid was a kind gift from the laboratory of Dr. Feng Cong, USA and this plasmid construct encodes a chimeric protein with the binding domain of E-cadherin fused to the beta-transducin repeat-containing protein (βTrCP) ubiquitin-protein ligase [16] . A previous study from our laboratory confirms F-TrCp-Ecad plasmid degrades cytosolic β-catenin in C1.1 cells [17] .
Western blot
Protein concentrations of lysates were estimated by BCA Protein Assay Kit (Thermo Fisher Scientific). Sample absorbance and protein concentrations were read with a Multilabel Reader Victor TM X3 (Perkin Elmer) using BSA standard curve.
Western blot samples were prepared by combining NuPAGE LDS sample buffer (Invitrogen), NuPAGE sample reducing agent (Invitrogen), the protein sample, and Millipore water to equate sample volumes. Wells were generally loaded with 30 µg of protein. The samples were placed on a 95°C heating block for 6 min to denature proteins and then loaded into 10% Mini-Protean TGX precast gels (Bio-Rad) with Novex Sharp pre-stained protein standard (Thermo Fisher Scientific). The gel was run at 100 V for 1 h 30 min by using 10x Tris-Glycine/SDS Buffer (Biorad) and gels were electrotransferred to nitrocellulose using a Transblot turbo Transfer Apparatus (Biorad). The membrane was blocked by 5% Skim milk in PBS at room temperature for 1 h and incubated with primary antibodies [anti-collagen I (1:1000; Abcam), anti-collagen III (1:1000, Abcam), anti-collagen IV (1:1000, Abcam), anti-N-cadherin, anti-vimentin (1:1000; Cell Signalling), anti-βcatenin (1:1000, BD Biosciences) overnight at 4°C in 5% skim milk diluted in PBST (Phosphate buffered saline with 0.1% Tween 20). After washes in PBST, horseradish peroxidase-conjugated secondary antibodies (1:2000) (Cell signaling) were incubated at room temperature for 1 h. Membranes were washed in PBST and developed using standard chemiluminescence with ECL (Advansta) and exposure to Chemi DocTM MP Imaging System (Biorad). To account for loading variability, all protein bands were normalized to β-actin or α-tubulin.
Co-immunoprecipitation
Co-immunoprecipitation (Co-IP) was performed according to the instructions on the Dynabeads® Protein G kit (Thermo Fisher Scientific). In brief, C1.1 cell lysates were extracted and then quantified using Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific). Co-IP was carried out with β-catenin (2 µg, BD Biosciences) or control IgG (Cell signalling) and bound to Dynabeads (Dynabeads-Ab). Between 400-600 μg of protein were incubated overnight at 4°C with the antibody (Dynabeads-Ab-Ag complex). The dynabeads were collected by Magnet Rack (Biorad). The supernatant was discarded and Dynabeads-Ab-Ag complex was washed and was eluted by boiling with premixed NuPAGE® LDS Sample Buffer and NuPAGE® Sample Reducing Agent (Thermofischer Scientific). The supernatant (bound proteins) were subjected to Western blot.
Proximity ligation assay (Duolink)
Proximity ligation assay (PLA) experiments were performed on C1.1 cells (grown in a four-well chamber slide system), paraffin-embedded mouse kidney sections and human kidney biopsies and analysed using the DUOLink kit (Sigma-Aldrich) according to the manufacturer's instructions. Briefly, either cells or deparaffinized tissues were fixed with 4% paraformaldehyde (Sigma) in PBS for 10 min and permeabilized with 0.5% Triton X-100 (Sigma) in PBS and blocked with blocking solution for 1 h at RT, then incubated with the primary antibodies, anti-mouse β-catenin (BD Transduction Laboratories) and anti-rabbit Foxo1 (Cell signaling) or anti-mouse β-catenin and antirabbit TCF1 (Cell signaling). Negative controls were obtained by omitting one of the primary antibodies. Secondary antibodies tagged with short DNA oligonucleotides were added. Hybridization, ligation and amplification were performed. Each slide was mounted with PLA mounting reagent containing DAPI and fluorescent spots visualized by confocal microscope and were counted by using Otsu thresholding Matlab software [18] . The number of PLA spots/100 nuclei was quantified in multiple [5] [6] [7] [8] microscopic fields (in tubular cell fields), averaged, and then used for statistical analysis.
Foxo reporter assay C1.1 cells were transfected using Cignal Foxo reporter kit from Qiagen with or without 1 µg F-TrCP-Ecad plasmid. After 24 h of treatment, cells were lysed and Firefly and Renilla luciferase activities were assessed using Dual-Glo luciferase assay system (Promega) by a luminometer (Wallac 1420 Victor Plate Reader, Perkin Elmer Life Sciences). The Firefly luciferase output was normalized against Renilla luciferase output.
TOP-flash assay
TOP-flash assay was performed as stated previously [17] in short, C1.1 cells were transfected with Top-flash or its mutant control FOP-flash at 1 µg/well and with pRL-RSV Renilla luciferase plasmid (0.1 µg/well) (Qiagen) as an internal control for transfection efficiency. After 12 h, cells were treated with TGF-β1 (3 ng/ml) and/or ICG-001 (5 μM). Cells were lysed, and luciferase activities were measured using a Dual-Glo luciferase assay system (Promega) in Wallac 1420 Victor Plate Reader. Relative luciferase activities were measured as the ratio of TOP-flash/FOPflash luciferase activity, each normalized against Renilla luciferase activity. The mean values of the normalized ratios were compared.
UUO model and treatment
Male Foxp3 gfp (Ly5.1) mice were a generous gift of Tim Sparwasser [19] . Male mice aged 8-10 weeks were used in all experiments. All mice were acquired from the specific pathogen-free laboratory Animal Care Centre of Westmead Hospital.
UUO was induced by ligation of the left ureter according to an established protocol described previously [20] . UUO and control mice were treated with rhTGF-β1 (50 µg/kg intraperitoneally) second daily or vehicle, with or without ICG-001 (5 mg/kg intraperitoneally) daily after surgery. Dose was selected according to previously published studies [6, 8] . Our previous study showed that administration of rhTGF-β and ICG-001 is effective and safe [6] . Mice were monitored daily and were sacrificed at 14 days after the operation. Kidneys were collected for the assessment of kidney fibrosis by western blot and immunostaining.
Immunohistochemical and immunofluorescence staining
For human kidney biopsies, the percentage of kidney fibrosis was assessed by a pathologist (CP) blinded to patient identification on the basis of Masson trichrome staining. The stained slides were scanned by Aperio scan scope and quantified using Image J by a blinded observer.
For immunofluorescence staining, deparaffinized slides were used. Initially, slides were deparaffinized and fixed with methanol and acetone at 1:1 volume. This was followed by heat antigen retrieval using sodium citrate buffer and then blocked with 2% BSA (Sigma) in PBS. Kidney sections were incubated with anti-collagen I (Abcam), anti-collagen III (Abcam), anti-collagen IV (Abcam), anti-Foxo1 (Cell signalling) or anti-β-catenin (BD Transduction Laboratories). To visualize the primary antibodies, sections were stained with Goat anti-rabbit Alexa Fluor 568 (ThermoFisher Scientific). Samples were stained with 4′, 6-diamidino-2 phenylindole (DAPI) (Sigma) to visualize the nuclei and mounted with mounting medium (Sigma-Aldrich) and viewed with a DeltaVision Elite Microscope by observers blinded to sample identification.
Fluorescence microscopy
Except for PLA (duo-link) of cells and animal tissues, imaging was performed by using a DeltaVision Elite Microscope comprising a wide-field inverted epifluorescence microscope (Olympus IX-71), Olympus 60X oil objective (PlanAPO, NA 1.42) and a CoolsSnapHQ2 (Roper Scientific) camera. Deconvolution (conserved ratio method) and other image processing were performed using SoftWoRx Suite 2.0 (Applied Precision, GE) and figures were built using Illustrator (Adobe Systems Inc., USA).
PLA images were acquired by Olympus FV 1000 confocal laser scanning microscope using Olympus IX-81 with an Olympus 60X Oil objective (UPLSAPO, NA 1.35). FV10-ASW 1.7 software was used to acquire the images. Image J software was used to quantify the images.
Statistical analyses
All data are presented as mean ± SEM. Statistical analyses of the data were performed using Graph Pad Prism 7 software. Comparison between groups was made using oneway ANOVA followed by Tukey test. Pearson correlation analysis was used for human data. P < 0.05 was considered statistically significant.
Study approval
All mouse studies were carried out in accordance with protocols approved by the Animal Ethics Committee of Western Sydney Local Health District. Formalin sections from human biopsy were obtained from Westmead Hospital and the study was approved by the Human Ethics Committee of Western Sydney Local Health District (approval no LNR/12/WMEAD/114 LNRSSA/12/WMEAD/117). All biopsies were clinically indicated, and only supplementary deidentified tissue was used for research purposes.
Results
Evidence for β-catenin/Foxo1 and β-catenin/TCF1 in human kidney biopsies β-catenin and Foxo1 are well conserved in structure and function between mouse and human. To assess the relevance of this to humans, we first examined the correlation between β-catenin/Foxo1 or β-catenin/TCF1 with the severity of kidney fibrosis (Fig. 1a ) in kidney biopsies of CKD patients, including those with thin glomerular basement membrane nephropathy (with 0-5% fibrosis score, considered as "kidney biopsies with little fibrosis"), hypertensive nephropathy, diabetic nephropathy, IgA nephropathy, FSGS, MCGN, medullary cystic diseases and kidney transplant using a PLA. This microscopy technique detects the interactions between two transcription factors [21] , in this case, TCF or Foxo with β-catenin. β-catenin/TCF1 correlated positively with fibrosis (r = 0.789 in transplant kidney biopsies, r = 0.944 in diabetic nephropathy, r = 0.919 in hypertensive nephropathy, r = 0.897 in IgA nephropathy, r = 0.653 in other kidney diseases and r = 0.805 overall, P < 0.001) while β-catenin/ Foxo1 correlated negatively with fibrosis (r = −0.756 in kidney transplants, r = -0.794 in diabetic nephropathy, r = −0.796 in hypertensive nephropathy, r = −0.917 in IgA nephropathy, r = −0.743 in other kidney diseases and r = −0.730 overall, P < 0.001) (Fig. 1) . These PLA studies showed colocalization of β-catenin and Foxo1 in tubular cells of kidney biopsies with little fibrosis (thin glomerular basement membrane disease) and colocalization of β-catenin and TCF1 in tubular cells of severe fibrosis biopsies. The PLA results were supplemented by single staining of β-catenin and Foxo1 (Supplemental Fig. 1 ). Tubular cells of kidney biopsies with little fibrosis showed increased Foxo1 expression and severe fibrosis biopsies showed decreased Foxo1 expression. Kidney biopsies of both little and severe fibrosis score showed β-catenin expression (Supplemental Fig. 1 ). Redirection of β-catenin binding from TCF1 to Foxo1 by rhTGF-β1 and ICG-001
To test the binding of β-catenin to Foxo1, we coimmunoprecipitated Foxo1 or TCF1 with β-catenin or IgG (as a control) from murine kidney tubular epithelial cells (C1.1) by treating with rhTGF-β1 plus either vehicle or ICG-001. The results showed that rhTGF-β1 promoted the association of TCF1 with β-catenin ( Fig. 2a) . However, the amount of Foxo1 associated β-catenin was not affected by rhTGF-β1 alone. ICG-001 is known to inhibit β-catenin/ TCF transcription by selectively blocking β-catenin/CBP interaction [22] . We found here that ICG-001 reduced βcatenin/TCF binding, while it increased the binding of βcatenin to Foxo1 in rhTGF-β1-treated C1.1 cells (Fig. 2a ). This result showed that Foxo competes with TCF1 in binding to β-catenin in tubular epithelial cells.
To corroborate the observed association of β-catenin and Foxo through rhTGF-β1 and ICG-001 treatment in C1.1, we performed PLA. The cells treated with rhTGF-β1 and ICG-001 showed a greater number of β-catenin/Foxo1 interactions (red spots) compared to those of control cells. TGF-β alone caused a significant increase in β-catenin/TCF signal (green) compared to control in C1.1 cells. ICG-001 alone increased β-catenin/Foxo1 interaction (apparent but not significantly) compared to control, as shown in Fig. 2b , c. However, with both rhTGF-β1 and ICG-001, β-catenin/Foxo1 interaction was increased significantly, indicating a shift of the β-catenin binding from TCF to Foxo1. Together with co-IP, PLA results showed direct evidence for redirection of β-catenin binding from TCF to Foxo by rhTGF-β1 and ICG-001.
In a functional Foxo reporter assay, treatment with rhTGF-β1 markedly reduced Foxo-luc activity in C1.1 cells. Conversely, Foxo reporter activity was increased (~4-fold) when β-catenin/TCF was inhibited by ICG-001 in the presence of rhTGF-β1 ( Fig. 2e ). However, targeted degradation of β-catenin by F-TrCP-Ecad plasmid transfection significantly decreased Foxo-luc transcriptional activity in rhTGF-β1 and ICG-001 treated C1.1 cells ( Fig. 2e ). We conclude that β-catenin is required for Foxo transcriptional activity in C1.1 cells. In a TOP-flash assay used for the detecting β-catenin/TCF activity, rhTGF-β1 treatment significantly increased β-catenin/TCF activity (~3-fold) in C1.1 cells. However, rhTGF-β1 and ICG-001 reduced the β-catenin/TCF luciferase activity (Fig. 2f ). These results demonstrate that inhibition of β-catenin/TCF interaction by ICG-001 along with rhTGF-β1 significantly increased β-catenin/Foxo activity.
β-catenin/Foxo1 protects against rhTGF-β1-induced profibrotic protein expression
Our previous study showed that co-administration of rhTGF-β1 and ICG-001 increased β-catenin/Foxo1-mediated anti-inflammatory effects via Tregs [6] . However, whether βcatenin/Foxo1 directly protects the tubular epithelial cell against profibrotic changes contributing to kidney fibrosis was not investigated. To address this, we targeted knocked-out Foxo1 and TCF genes using their CRISPR/cas9 KO plasmids in C1.1 cells (Fig. 3a) .
Firstly, we performed CRISPR/cas9-mediated Foxo1 knockout (KO) in C1.1 cells to identify whether Foxo1 protects against expression of a set of proteins associated with fibrosis. Western blot analyses showed that rhTGF-β1 treatment induced the expression of collagen I, N-cadherin and vimentin in wild-type C1.1 cells (Fig. 3b, lane 2) . The combined treatment of rhTGF-β1 and ICG-001 reduced collagen I, N-cadherin and vimentin expression to basal levels (in Fig. 3b , compare lane 3 with lane 2). However, in Foxo1 KO C1.1 cells, the reduction in rhTGF-β1-induced collagen I, N-cadherin and vimentin expression by ICG001 treatment was abolished in absence of Foxo1 (in Fig. 3b , compare lane 7 with lane 3), showing a dependence on Foxo1 in ICG-001-mediated reduction of profibrotic changes.
In parallel, we also performed TCF1 KO in the C1.1 cell lines using CRISPR/cas9 TCF1 KO plasmid. C1.1 (Wild-Type) and TCF1 KO cells were transiently transfected with F-TrCP-Ecad plasmid to degrade cytosolic β-catenin. In F-TrCP-Ecad transfected C1.1 cells, TGF-β1-induced collagen I, N-cadherin and vimentin expression was significantly reduced compared to that of rhTGF-β1-treated wild-type C1.1 cells (in Fig. 3c , lane 4 compare with lane 3), demonstrating a β-catenindependent profibrotic effect generally believed to be through β-catenin/TCF. This was confirmed by combined treatment with rhTGF-β1 and ICG-001, in which β-catenin/TCF interaction was inhibited by ICG-001 (Fig. 3c , lane 5). However, inhibition of β-catenin/TCF interaction by ICG-001 with rhTGF-β1 showed a greater reduction of profibrotic protein levels than those seen when β-catenin was degraded by F-TrCP-Ecad (in Fig. 3c , compare lane 5 with lane 6). In absence of β-catenin in F-TrCP-Ecad transfected C1.1 cells, ICG-001 was ineffective in the combined treatment with rhTGF-β1 and ICG-001 (in Fig. 3c, compare lane 6 with lane 4) . TCF1 KO significantly reduced rhTGF-β1-induced expression of collagen I, N-cadherin, and vimentin compared with rhTGF-β1-treated wild-type C1.1 cells (in Fig. 3c , compare lane 10 with lane 3). β-catenin is known to bind to either TCF or Foxo in competition [23] . In TCF KO C1.1 cells, β-catenin uses Foxo as its binding partner. However, degradation of β-catenin by F-TrCP-Ecad increased the levels of rhTGF-β1-induced collagen I, N-cadherin and vimentin (in Fig. 3c, compare lane 10 with lane 11) . This result shows that β-catenin binding to Foxo is required to protects against rhTGF-β1-induced profibrotic changes. Taken together, our results showed that promotion of βcatenin/Foxo1, in addition to inhibition of β-catenin/TCF, protects against TGF-β1-induced profibrotic changes.
Immunofluorescence staining confirmed the findings of Western blot analysis of vimentin. As shown in Fig. 4 , combined treatment of rhTGF-β1 and ICG-001 in wildtype C1.1 cells reduced vimentin expression. In Foxo1 KO C1.1 cells, the inhibitory effect of ICG-001 on rhTGF-β1-induced vimentin expression was reduced. The lesser reduction of TGF-β-induced vimentin expression is consistent with the absence β-catenin/Foxo, whereas in WT cells, ICG-001 inhibition of β-catenin/ TCF also increases β-catenin/Foxo, and thereby further reduces vimentin expression. In TCF1 KO cells, rhTGF-β1-induced vimentin expression was suppressed ( Fig. 4) .
Collectively, the results demonstrate that ICG-001, an inhibitor of β-catenin/TCF, along with rhTGF-β1 promotes activation of β-catenin/Foxo1 in C1.1 cells and protects against TGF-β1-induced profibrotic proteins.
rhTGF-β1 and ICG-001 reduces kidney fibrosis in obstructed kidney
Having demonstrated the protective role of β-catenin/Foxo1 in C1.1 cells by inhibiting β-catenin/TCF via ICG-001 and rhTGF-β1, we then sought to determine if β-catenin/Foxo1 protects against kidney fibrosis in vivo. To this end, ICG-001 was administered intraperitoneally to Foxp3 GFP mice after unilateral ureteral obstruction (UUO) at dosages of 5 mg/kg body weight daily and rhTGF-β1 at 50 μg/kg body weight every two days. We evaluated the effect of rhTGF-β1 and ICG-001 treatment on kidney fibrosis using collagen expression, specifically that of collagen I, collagen III and collagen IV. Administration of rhTGF-β1 and ICG-001 significantly reduced interstitial staining for collagen I, collagen III and collagen IV, as compared to that of untreated UUO mice (Fig. 5b) which was confirmed by Western blot (Supplemental Fig. 2) . Importantly, mice administered rhTGF-β1 and ICG-001 showed greater attenuation of these morphologic lesions than seen with ICG-001 treatment alone. This is consistent with our previous study [10] , which showed that combined treatment with rhTGF-β1 and ICG-001 reversed the anti-inflammatory effects of rhTGF-β1 by a β-catenin/Foxo1-dependent increase in Tregs, while the β-catenin/TCF-dependent fibrosis was inhibited by ICG001. However, the current in vitro study showed that the combined treatment also protected profibrotic changes directly in tubular epithelial cells in a β-catenin/Foxo1-dependent manner, an additional mechanism which explains the greater protection of the combined treatment. To investigate this further, we examined β-catenin/Foxo1 and β-catenin/TCF interactions in the UUO kidney.
Shifting of β-catenin from TCF to Foxo1 by rhTGF-β1 and ICG-001 in obstructed injury
To examine whether β-catenin/Foxo1 underlies the protection of kidney fibrosis in UUO mice by combined treatment with rhTGF-β1 and ICG-001, we employed PLA. PLA analysis of kidney sections showed a significantly higher PLA signal for β-catenin/Foxo1 predominantly in tubules (shown by the differential interference contrast (DIC) images of tubular morphology outlined in Fig. 6a ) of UUO mice treated with rhTGF-β1 and ICG-001 compared with all other groups (Fig. 6a ). The PLA results were supplemented by immunofluorescence staining for β-catenin and Foxo1 in Fig. 3 ). β-catenin/ TCF was significantly increased in the kidney tubular cells of UUO mice, and further increased with rhTGF-β1 only treatment, but significantly reduced by combined treatment with rhTGF-β1 and ICG-001 ( Fig. 6b) . These results provide in vivo evidence that co-administration of rhTGF-β1 and ICG-001 in UUO mice indeed shifted β-catenin from TCF to Foxo in protecting against fibrosis.
Discussion
Interaction between transcription factors is recognized as a new mechanism for diverse functions of cytokines such as TGF-β. TCF and Foxo are two transcription co-factors that bind to β-catenin in competition. Depending on the key binding partner of β-catenin, for example TCF or Foxo, the response of target cells to TGF-β signaling can be quite different, even in opposite directions [6, 23, 24] . Therefore, it is important to identify the various key transcription cofactors that determine a cytokine's function. Activation of β-catenin/TCF targeted genes is a common feature of fibrosis [25] , which promotes proliferation of myofibroblasts and expression of fibrotic genes [26] . ICG-001 has been shown effective in inhibition of β-catenin/TCF-mediated fibrosis [6, 27, 28] . Our previous study proved that inhibition of β-catenin/TCF not only prevented β-catenin/TCF-mediated fibrosis in kidney, but also shifted Fig. 6 PLA analysis of β-catenin/Foxo1 and β-catenin/TCF interactions in tubular cells in UUO kidney. a Representative β-catenin/ Foxo1 (red spot) and b β-catenin/TCF (green spot) interaction in kidney sections of control, untreated UUO, and UUO mice treated with rhTGF-β1, rhTGF-β1 and ICG-001, or ICG-001 only. Nuclei were stained with DAPI. Fluoroscence images were merged with differential interference contrast (DIC) images to show the localization of PLA signals in tubular cells (indicated by broken lines). Original magnification, X60. c, d Quantitation data of PLA signals by one-way ANOVA followed by Tukey post hoc test. Results are shown as mean ± SEM (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 β-catenin/TCF to β-catenin/Foxo1 which promoted TGF-β's anti-inflammatory effects via upregulation of Tregs [6] . This novel observation explains how conflicting profibrotic and anti-inflammatory roles of TGF-β can be dissociated to maximize the therapeutic effect of targeting TGF-β. However, whether β-catenin/Foxo1 protects directly against profibrotic effects in tubular cells in addition to its antiinflammatory function was unknown and not investigated in that study. In the current study, we used CRISPR/cas9mediated Foxo and TCF knockout in vitro, and showed a novel protective role for β-catenin/Foxo against profibrotic signaling of TGF-β. In addition, rhTGF-β1 and ICG-001 was found to be protective against kidney fibrosis in a murine model of UUO. Thus, we showed that binding of βcatenin to Foxo not only diverted the limited pool of βcatenin away from TCF to inhibit fibrosis, but also that βcatenin/Foxo per se was protective against fibrosis.
In this study, we characterized for the first time β-catenin/Foxo1 and β-catenin/TCF expression in human kidney biopsies by PLA and their association with kidney fibrosis. Our findings in tubular cells of patient biopsies lend strong support to a protective role of β-catenin/Foxo1 against kidney fibrosis. Kidney fibrosis in biopsies of patients with diabetic nephropathy, IgA nephropathy, hypertensive nephropathy, FSGS, MCGN, medullary cystic diseases and kidney transplant exhibited a strong positive correlation with levels of β-catenin/TCF and inverse correlation with βcatenin/Foxo1. The reciprocal relationship between levels of β-catenin/TCF and β-catenin/Foxo1 are consistent with competition between Foxo1 and TCF in binding to βcatenin. PLA is an established method to visualize binding or interaction between proteins; here we have used it for the first time to determine interactions between β-catenin/TCF and β-catenin/Foxo1 that are pivotal to progression of human disease. Importantly, the same antibodies were used to identify β-catenin/Foxo1 and β-catenin/TCF interactions in murine tissues and human kidney biopsy samples, not only proving the conservation of protein structure of those transcription factors between human and mouse, but also providing evidence for the relevance of findings in the mouse model to human CKDs.
These studies are the first to examine β-catenin/Foxo1 and β-catenin/TCF expression by PLA in both in vitro and in vivo experiments. The PLA analysis in both in vitro and in vivo experiments provides direct evidence for the promotion of β-catenin/Foxo through inhibition of β-catenin/ TCF by ICG-001 together with rhTGF-β1 treatment. Collectively, human, and in vitro and in vivo animal data demonstrate a pivotal role for β-catenin/Foxo in protecting against kidney fibrosis.
Importantly this study was able to prove the protective role of β-catenin/Foxo1 by using CRISPR/cas9 KO of Foxo1 or TCF in C1.1 cells. By CRISPR/cas9 knockout of Foxo1, we identified the dependence on Foxo1 of protection against TGF-β induced profibrotic changes in C1.1 cells. Meanwhile, we also identified the necessity of β-catenin for Foxo activity in protecting against TGF-β-induced profibrotic changes in tubular cells by altering β-catenin levels using F-TrCP-Ecad in wild-type and TCF KO C1.1 cells. Thereby, a β-catenin/Foxo1-dependent protective effect in tubular epithelial cells was established. In addition, we showed a reduction of kidney fibrosis in UUO mice treated with rhTGF-β1 when combined with ICG-001, accompanied with upregulation of β-catenin/Foxo1 in tubules as an additional mechanism for the greater protection by rhTGF-β1 and ICG001 than by ICG001 alone treatment.
In this study we have demonstrated a β-catenin/Foxo1dependent protective effect in tubular epithelial cells indirectly by deletion of Foxo1. Ideally, a selective β-catenin/ Foxo1 inhibitor is required to prove dependence on βcatenin/Foxo in protection against TGF-β1-induced profibrotic changes. However, no specific β-catenin/Foxo inhibitor have been developed so far. Alternatively, we used βcatenin degradation (F-TrCP-Ecad) in absence of TCF (TCF1 KO C1.1 cells) to prevent Foxo1 binding to βcatenin, to prove the protective role of Foxo1 binding to βcatenin.
In summary, our study shows that β-catenin/Foxo1 protects against TGF-β induced profibrotic effects directly in tubular epithelial cells, independent of its role in Tregs and may serve as a novel target for treatment of human kidney fibrosis.
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